Broker Meeting 23 Feb

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Have a great Sunday, especially those of you like me that are celebrating Orthodox Easter ... As well as those of you who are also like me and mourning another Maple Leafs Game 7 exit ... Ugggh!

Sincerely,

George et al

Reply New Message

Prev Message Back To Forum Threaded View Next Message

tada

Rank: President [?]

Points: 7673 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Broker Meeting 23 Feb

posted on Feb 28, 2017 09:05PM

There was a broker meeting at the Zenith Epigenetics Ltd offices in Calgary on 23 Feb. It was actually an RVX meeting but there were a couple of comments about Zenith so I will post them here.

The Phase I CRPC trial continues. They are still on the first cohort of the ZEN3694 and Enzalutamide combination. They are very encouraged as to the results they are getting so far. The longest dosed patient on ZEN3694 is now 7 months. The next phase of this trial after this current combination is finished, will be in combination with a breast cancer drug. They have been in conversations with a company that is considering doing a combination trial with a lung cancer drug. Money is not an issue at this time as they were financed last year and the coffers have plenty in them at this time.

These notes were put together after talking with 3 people who were at this meeting. If you know of someone who was at the meeting and made notes please post them if you can.